• The objective of this study was to evaluate whether TKIs can be discontinued in these selected patients with mRCC
• A retrospective analysis of medical records and imaging studies was performed on all patients with mRCC treated with TKIs (n= 266) in 5 institutions. Patients with a complete remission under TKI treatment alone or with additional metastasectomy following a partial response, in which TKIs were subsequently discontinued, were included in the analysis
• Outcome criteria analyzed were time to recurrence of previous metastases, occurrence of new metastases, symptomatic progression, improvement of adverse events, and response to re-exposure to TKIs
Copyright © 